最新ニュース Cognex (NASDAQ:CGNX) 株価情報

Cognex

Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's own cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.

Cognex Corp

WIIM

AEIS

ALGM

ANET

AVGO

AWRE

BELFB

BOXL

CAMT

CGNX

CLMB

CMTL

CNXN

COHR

CSCO

DELL

DGII

DIOD

EVLV

EXTR

FFIV

FLEX

FORM

FRSH

IONQ

IPGP

KEYS

KODK

LASR

LITE

NOVT

NTAP

NTCT

NVEC

Next Technology Holding Inc. - Ordinary Shares

NXTT

OSIS

PLUS

PLXS

PMTS

PSTG

QMCO

QTWO

SANM

SCSC

SITM

TTMI

VIAV

WOLF

ZBRA

Shares of companies within the broader technology sector are trading higher in sympathy with overall market strength after Donald Trump was elected president of the United States.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58407d80aae83900016b3bd0/bryan-keane">Deutsche Bank analyst Bryan Keane</a> downgraded the rating for Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Hold and lowered the price target from $9 to $4. Marqeta shares closed at $5.95 on Monday. <a href="https://www.benzinga.com/quote/MQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Jamie Cook downgraded Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and slashed the price target from $46 to $43. Cognex shares closed at $40.85 on Monday. <a href="https://www.benzinga.com/quote/CGNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Reni Benjamin downgraded the rating for Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) from Market Outperform to Market Perform. Sana Biotechnology shares closed at $3.76 on Monday. <a href="https://www.benzinga.com/quote/SANA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/603e4f87b3e2040001080043/tessa-romero">JP Morgan analyst Tessa Romero</a> downgraded Neumora Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) from Overweight to Neutral and lowered the price target from $18 to $15. Neumora Therapeutics shares closed at $11.71 on Monday. <a href="https://www.benzinga.com/quote/NMRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Christopher Liu downgraded the rating for IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Outperform to Market Perform and lowered the price target from $41 to $27. IDEAYA Biosciences shares closed at $30.00 on Monday. <a href="https://www.benzinga.com/quote/IDYA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CGNX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="533" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-1024x533.png" alt="" class="wp-image-630098" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-1024x533.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27.png 1272w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

News

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

IDYA

NMRA

SANA

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Truist Securities analyst Jamie Cook downgrades Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and lowers the price target from $46 to $43.

Price Target

Truist Securities Downgrades Cognex to Hold, Lowers Price Target to $43

Needham analyst James Ricchiuti maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Buy and lowers the price target from $50 to $47.

Needham Maintains Buy on Cognex, Lowers Price Target to $47

Guidance

Cognex Sees Q4 2024 Revenue $210M-$230M

Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.19 by 5.26 percent. The company reported quarterly sales of $234.74 million which beat the analyst consensus estimate of $233.03 million by 0.74 percent. This is a 19.01 percent increase over sales of $197.24 million the same period last year.

Earnings

Earnings Beats

Cognex Q3 2024 Adj EPS $0.20 Beats $0.19 Estimate, Sales $234.74M Beat $233.03M Estimate

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">PBF Energy</h3>
<ul>
<li>The Trade: PBF Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) 10% owner Control Empresarial de Capitales S.A. de C.V.<a href="https://www.benzinga.com/quote/PBF/analyst-ratings"> acquired a total of 1,210,000 shares at</a> an average price of $33.25. To acquire these shares, it cost around $40.2 million.</li>
<li>What's Happening: PBF Energy will release its earnings results for the third quarter 2024 on Thursday, Oct. 31.</li>
<li>What PBF Energy Does: PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States.</li>
</ul>
<h3 class="wp-block-heading">Talos Energy</h3>
<ul>
<li>The Trade: Talos Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) 10% owner Control Empresarial de Capitales S.A. de C.V. acquired a total of 2,397,000 shares at an average price of $11.08. To acquire these shares, it cost around $26.5 million.</li>
<li>What's Happening: The company disclosed that its Ewing Bank 953 well has successfully discovered commercial quantities of oil and natural gas.</li>
<li>What Talos Energy Does: Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production.</li>
</ul>
<h3 class="wp-block-heading">Cognex</h3>
<ul>
<li>The Trade: Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) SVP, Chief Financial Officer Dennis Fehr <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 6,570 shares</a> at an average price of $38.04. To acquire these shares, it cost around $249,920.</li>
<li>What's Happening: On July 31, Cognex reported mixed second-quarter financial results.</li>
<li>What Cognex Does: Cognex Corp provides machine vision products that help automate manufacturing processes.</li>
</ul>
<h3 class="wp-block-heading">Lululemon Athletica</h3>
<ul>
<li>The Trade: Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) CEO Calvin McDonald <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 4,000 shares</a> at an average price of $260.00. The insider spent around $1.04 million to buy those shares.</li>
<li>What's Happening: On Aug. 29, Lululemon Athletica reported better-than-expected second-quarter EPS results.</li>
<li>What Lululemon Athletica Does: Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy"> </a>
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy">Jim Cramer: Oklo Is Losing Money &#8216;Hand-Over-Fist,&#8217; But This Private Equity Stock Is A Buy</a></li>
</ul>

Long Ideas

Insider Trades

LULU

TALO

Over $40M Bet On PBF Energy? Check Out These 4 Stocks Executives Are Buying

AAPL

AEVA

ASNS

BBAI

Core Scientific, Inc. - Class A Common Stock

CORZ

CRSR

DAKT

DOCN

DTST

EGIO

FIVN

GDDY

GTLB

KOPN

LWLG

NSIT

SHOP

SNOW

VECO

Shares of companies within the broader tech sector are trading lower amid overall market weakness. Weakness may be due to August's ISM Manufacturing PMI data indicating an economic contraction.

DA Davidson analyst Matthew Summerville maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Neutral and lowers the price target from $41 to $39.

DA Davidson Maintains Neutral on Cognex, Lowers Price Target to $39

Stephens &amp; Co. analyst Tommy Moll reiterates Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Equal-Weight and maintains $45 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Cognex, Maintains $45 Price Target

ADBE

APLD

BILL

BRZE

CDNS

COMM

DDOG

DOCU

ERIC

ESTC

FSLR

GOOG

GOOGL

INFY

INTC

INTU

IREN

MRVL

MSFT

NTNX

NVDA

OKTA

ORCL

OUST

PANW

PCOR

PLTR

QRVO

SMCI

SMTC

SWKS

TOYO

TRMB

TWLO

VSAT

WDAY

ZETA

Shares of stocks in the broader tech sector are trading lower as stocks sell off amid concerns over the US economy.

Baird analyst Richard Eastman maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Neutral and lowers the price target from $46 to $42.

Baird Maintains Neutral on Cognex, Lowers Price Target to $42

Goldman Sachs analyst Joe Ritchie maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Sell and lowers the price target from $45 to $39.

Goldman Sachs Maintains Sell on Cognex, Lowers Price Target to $39

Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) reported mixed second-quarter financial results, after the<a href="https://www.benzinga.com/quote/CGNX"> closing bell on Wednesday</a>.
Cognex reported quarterly earnings of 23 cents per share which beat the analyst consensus estimate of 21 cents per share. The company reported quarterly sales of $239.00 million which missed the analyst consensus estimate of $240.39 million.
&#8220;Cognex delivered second quarter revenue and gross margin in line with expectations and operating expenses favorable to our guidance,&#8221; said Robert J. Willett, CEO. &#8220;Year-on-year revenue growth in the quarter was strong in our Logistics and Semiconductor end markets, however revenue across the rest of our factory automation business continues to be soft.&#8221;
Cognex shares fell 21.2% to close at $39.08 on Thursday.
These analysts made changes to their price targets on Cognex following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/591b27b4290fa70001b1563e/james-ricchiuti">Needham analyst James Ricchiuti </a>maintained Cognex with a Buy and lowered the price target from $57 to $50.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ac4af1b85e930001e6383a/jamie-cook">Truist Securities analyst Jamie Cook </a>maintained Cognex with a Buy and lowered the price target from $55 to $46.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40122820/amazon-apple-and-3-stocks-to-watch-heading-into-friday">Amazon, Apple And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

These Analysts Cut Their Forecasts On Cognex Following Q2 Results

Truist Securities analyst Jamie Cook maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Buy and lowers the price target from $55 to $46.

Truist Securities Maintains Buy on Cognex, Lowers Price Target to $46

Needham analyst James Ricchiuti maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Buy and lowers the price target from $57 to $50.

Needham Maintains Buy on Cognex, Lowers Price Target to $50

Cognex shares are trading lower after the company reported mixed Q2 financial results.

Cognex Expects Q3 Revenue of $225M-$240M, Slight Sequential Decrease From Q2 But Slight YoY Increase Excluding Moritex; Moritex To Contribute 10%-12% of Q3 Revenue; Adjusted Gross Margin Slightly Below 70%; Adjusted EBITDA Margin 16%-19%; Adjusted Effective Tax Rate 16%

Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.21 by 9.52 percent. The company reported quarterly sales of $239.00 million which missed the analyst consensus estimate of $240.39 million by 0.58 percent. This is a 1.45 percent decrease over sales of $242.51 million the same period last year.

Earnings Misses

Cognex Q2 2024 Adj EPS $0.23 Beats $0.21 Estimate, Sales $239.00M Miss $240.39M Estimate

Cognex raises quarterly dividend by 6.7% to  $0.08/share

Cognex Corporation (CGNX) Q3 2024 Earnings Call Transcript

Cognex Corporation 2024 Q3 - Results - Earnings Call Presentation

Cognex ( ($CGNX) ) has released its Q3 earnings. Here is a breakdown of the information Cognex presented to its investors. Cognex Corporation is a ...

Cognex Reports Solid Q3 2024 Financial Performance

KeyBanc analyst Kenneth Newman maintained a Hold rating on Cognex (CGNX – Research Report) today. The company's shares closed yesterday at $40.23. ...

Cognex (CGNX) Receives a Hold from KeyBanc

Dividend Champion, Contender, And Challenger Highlights: Week Of November 3

D.A. Davidson analyst Matt Summerville maintained a Hold rating on Cognex (CGNX – Research Report) today and set a price target of $39.00. The comp...

Cognex (CGNX) Receives a Hold from D.A. Davidson

Truist analyst Jamie Cook downgraded Cognex (CGNX) to Hold from Buy with a price target of $43, down from $46, following mixed Q3 results. The firm...

Comments

Cognex

ニュース

最新ニュース Cognex (NASDAQ:CGNX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル